Key Takeaways

  • The location of geographic atrophy lesions—especially when affecting the central retina—has a greater impact on patients’ daily functioning and quality of life than overall lesion size alone
  • Patients with foveal or near-foveal involvement report significantly more difficulty with tasks like reading, recognizing faces, and navigating environments
  • Incorporating lesion topography into clinical assessment and trial design could improve patient care and provide more meaningful measures of treatment effectiveness

A newly published study in the journal Ophthalmology is shedding light on how the location of retinal damage—not just its severity—can significantly shape how patients experience vision loss and daily life.1

The research focuses on geographic atrophy (GA) and examins how the topographic distribution of lesions affects patients’ vision-related quality of life (VR-QoL). Rather than treating all GA cases as equivalent, researchers found that the specific placement of lesions plays a crucial role in determining how much a patient’s daily functioning is impacted.

The study reports that lesions affecting central areas of the retina—particularly those near the fovea—are strongly associated with worse patient-reported outcomes. Patients with centrally located damage were more likely to report difficulty with everyday tasks such as reading, recognizing faces, and navigating their environment. By contrast, individuals whose lesions were more peripheral tended to retain better functional vision, even if the overall disease burden appeared similar.

Traditionally, clinicians have focused on the size or total area of retinal damage when evaluating GA. But this study suggests that approach may miss a key part of the picture. Instead, the findings indicate that where the damage occurs may be just as important as how much damage exists—and in some cases, even more predictive of how patients feel and function.

The researchers say these insights could influence both patient care and the development of new therapies.

  • Clinical care: Doctors may need to incorporate lesion location into routine assessments to better predict patient needs and tailor interventions
  • Drug development: Future clinical trials could use more nuanced endpoints that account for lesion placement, potentially improving how treatment benefits are measured

Reference

1. Anegondi N, Lam D, Guymer R, et al. Vision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution. Ophthalmology, 2026.